AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases
Association Recommends Policy Solutions To Congress As Proposals To Lower Prices Unveiled
The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”
